Posts Tagged ‘diabetes’

The market for precision nutrition advice is more than six billion dollars today and estimated to double by the end of this decade. Sales of continuous glucose monitoring devices are on their way to $20 billion within three years. But a new study this week in the American Journal of Clinical Nutrition suggests that the […]

A new study presented at the Annual Scientific Sessions of the American College of Gastroenterology tells us receiving a GLP-1 for diabetes with or without obesity is associated with a halving of pancreatic cancer risk. Is this too good to be true? Observational, of Course The first thing to note is that the finding comes […]

Is the glass half full? Or 99% empty? The metaphorical glass in this case is the number of people with a legitimate indication for the remarkable prescription drug generically known as semaglutide. Ivy Shi et al presented an elegant answer at the AHA Scientific Sessions this week and simultaneously published it in JAMA Cardiology. They […]

Amid a steady stream of news from ObesityWeek, the CDC released new NHANES data this week documenting an ongoing rise in U.S. diabetes prevalence. Between 1999 and 2023, the age-adjusted prevalence of diabetes, diagnosed and undiagnosed, in adults rose from 9.7% to 14.3%. The total prevalence in adults between 2021 and 2023 was 15.8% – […]

People who think of obesity simply as a disease of fatness are walking around with a profound misunderstanding of this disease – it is very much a disease of inflammation. This thread of inflammation ties obesity to diabetes and ties both of those diseases to the complications of COVID. New research on COVID and diabetes […]

Yesterday, Eli Lilly and Company announced an impressive topline number from the results of a three-year study of tirzepatide in adults with obesity or overweight and prediabetes. That number was 94% prevention of progression from prediabetes to diabetes with tirzepatide. No, it was not 100%. But this is awfully close. Historical Context We will have to […]

When the subject of equitable access to GLP-1s arises, contrasting perspectives of what is equitable become apparent. Last week in the Annals of Internal Medicine, an analysis of prescription data for GLP-1 agonists made two facts about their use very clear. First, their use for obesity is growing much faster than the use for type […]

Liver disease is frighteningly common worldwide. Metabolic dysfunction-associated steatotic liver disease, or MASLD, is an umbrella term describing conditions related to a buildup of fat in the liver. Formerly known as nonalcoholic fatty liver disease, this condition affects 1 in 4 people worldwide. Among those with type 2 diabetes, insulin resistance, obesity, or all three, […]

Every day is a day to learn something new. So yesterday we learned that our gut has a mind of its own – the enteric nervous system. Randy Seeley presented his work on this at the Columbia Cornell Obesity Medicine course. It seems that much of the progress in obesity treatment over the last few […]

We’re stuck. This assessment sums up frustration with efforts to reduce the harm of obesity and diabetes in public health. For many decades we have remained fixated on a paradigm that tells us obesity and diabetes are rising because our patterns of diet and exercise are all wrong. Writing in the Guardian, Amy McLennan tells […]